Bastian Dehmel

Corporate Officer/Principal chez OCULIS HOLDING AG

54 ans

Health Technology

Consumer Services

Postes actifs de Bastian Dehmel

Sociétés	Poste	Début	Fin
OCULIS HOLDING AG	Corporate Officer/Principal	01/01/2022	-

Sociétés	Poste	Début	Fin
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Directeur Technique/Scientifique/R&D	01/10/2017	01/12/2021
Amgen (Europe) GmbH	Corporate Officer/Principal	01/12/2013	01/07/2017

Freie Universität Berlin

Doctorate Degree

Internationale

Opérationnelle

Corporate Officer/Principal	2
Chief Tech/Sci/R&D Officer	1
Doctorate Degree	1

Sectorielle

Health Technology	3
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
OCULIS HOLDING AG	Health Technology

Entreprise privées	2
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology
Amgen (Europe) GmbH

Entreprise privées

Health Technology

Amgen (Europe) GmbH